• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原位从微乳液向液晶相转变,具有延长的注射药物输送潜力。

In-situ phase transition from microemulsion to liquid crystal with the potential of prolonged parenteral drug delivery.

机构信息

School of Pharmacy, The University of Auckland, Auckland, New Zealand.

出版信息

Int J Pharm. 2012 Jul 15;431(1-2):130-7. doi: 10.1016/j.ijpharm.2012.04.020. Epub 2012 Apr 23.

DOI:10.1016/j.ijpharm.2012.04.020
PMID:22548845
Abstract

This study is the first to investigate and demonstrate the potential of microemulsions (MEs) for sustained release parenteral drug delivery, due to phase transition behavior in aqueous environments. Phase diagrams were constructed with Miglyol 812N oil and a blend of (co)surfactants Solutol HS 15 and Span 80 with ethanol. Liquid crystal (LC) and coarse emulsion (CE) regions were found adjacent to the ME region in the water-rich corner of the phase diagram. Two formulations were selected, a LC-forming ME and a CE-forming ME and each were investigated with respect to their rheology, particle size, drug release profiles and particularly, the phase transition behavior. The spreadability in an aqueous environment was determined and release profiles from MEs were generated with gamma-scintigraphy. The CE-forming ME dispersed readily in an aqueous environment, whereas the LC-forming ME remained in a contracted region possibly due to the transition of ME to LC at the water/ME interface. Gamma-scintigraphy showed that the LC-forming ME had minimal spreadability and a slow release of (99m)Tc in the first-order manner, suggesting phase conversion at the interface. In conclusion, owing to the potential of phase transition, LC-forming MEs could be used as extravascular injectable drug delivery vehicles for prolonged drug release.

摘要

这项研究首次通过水相中的相转变行为,研究并证明了微乳液(MEs)在经肠胃外给药的缓释中的潜力。利用 Miglyol 812N 油和(共)表面活性剂 Solutol HS 15 和 Span 80 与乙醇构建了相图。在相图的水相富区,发现了与 ME 区相邻的液晶(LC)区和粗乳液(CE)区。选择了两种配方,一种是形成 LC 的 ME,另一种是形成 CE 的 ME,并分别对其流变学、粒径、药物释放曲线进行了研究,特别是相转变行为。在水相中的铺展性进行了测定,并通过γ闪烁照相法生成了 ME 的释放曲线。CE 形成的 ME 很容易在水相环境中分散,而 LC 形成的 ME 可能由于 ME 在水/ME 界面处向 LC 的转变而保持在收缩区。γ闪烁照相法表明 LC 形成的 ME 的铺展性最小,并且(99m)Tc 以一级方式缓慢释放,表明界面处发生了相转变。总之,由于相转变的潜力,LC 形成的 ME 可用作延长药物释放的血管外注射药物递送载体。

相似文献

1
In-situ phase transition from microemulsion to liquid crystal with the potential of prolonged parenteral drug delivery.原位从微乳液向液晶相转变,具有延长的注射药物输送潜力。
Int J Pharm. 2012 Jul 15;431(1-2):130-7. doi: 10.1016/j.ijpharm.2012.04.020. Epub 2012 Apr 23.
2
A study of microemulsions as prolonged-release injectables through in-situ phase transition.通过原位相转变研究微乳液作为缓控释注射剂。
J Control Release. 2014 Jan 28;174:188-94. doi: 10.1016/j.jconrel.2013.11.022. Epub 2013 Dec 5.
3
In situ phase transition of microemulsions for parenteral injection yielding lyotropic liquid crystalline carriers of the antitumor drug bufalin.微乳液的原位相转变为注射用的溶致液晶载体,用于抗肿瘤药物蟾毒灵。
Colloids Surf B Biointerfaces. 2019 Jan 1;173:217-225. doi: 10.1016/j.colsurfb.2018.09.023. Epub 2018 Sep 11.
4
Development of water-in-oil microemulsions with the potential of prolonged release for oral delivery of L-glutathione.开发具有延长释放潜力的油包水乳状液,用于口服 L-谷胱甘肽。
Pharm Dev Technol. 2013 Nov-Dec;18(6):1424-9. doi: 10.3109/10837450.2012.734518. Epub 2013 Jun 6.
5
Investigation of self-microemulsifying and microemulsion systems for protection of prednisolone from gamma radiation.研究自微乳和微乳体系对泼尼松龙的γ 射线辐射保护作用。
Pharm Dev Technol. 2011 Jun;16(3):237-42. doi: 10.3109/10837451003610829. Epub 2010 Feb 11.
6
Percutaneous delivery of econazole using microemulsion as vehicle: formulation, evaluation and vesicle-skin interaction.经皮递送酮康唑微乳作为载体:制剂、评价及囊泡-皮肤相互作用。
Int J Pharm. 2014 Apr 25;465(1-2):120-31. doi: 10.1016/j.ijpharm.2014.02.012. Epub 2014 Feb 12.
7
Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: effect of phase transition.自微乳和微乳体系透皮传递吲哚美辛:相变的影响。
Colloids Surf B Biointerfaces. 2010 Feb 1;75(2):595-600. doi: 10.1016/j.colsurfb.2009.10.003. Epub 2009 Oct 13.
8
Oil-in-water lecithin-based microemulsions as a potential delivery system for amphotericin B.水包油型卵磷脂微乳剂作为两性霉素B的潜在递送系统。
Colloids Surf B Biointerfaces. 2008 Oct 15;66(2):253-9. doi: 10.1016/j.colsurfb.2008.06.016. Epub 2008 Jul 4.
9
Development of cyclosporine A microemulsion for parenteral delivery.用于肠胃外给药的环孢素A微乳剂的研发。
J Microencapsul. 2015;32(3):273-80. doi: 10.3109/02652048.2015.1010461. Epub 2015 Mar 12.
10
W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention.用于眼部给药的油包水型微乳剂:眼部刺激性和角膜前滞留性评估
J Control Release. 2006 Mar 10;111(1-2):145-52. doi: 10.1016/j.jconrel.2005.11.020. Epub 2006 Jan 19.

引用本文的文献

1
Microemulsions of Nonionic Surfactant with Water and Various Homologous Esters: Preparation, Phase Transitions, Physical Property Measurements, and Application for Extraction of Tricyclic Antidepressant Drugs from Aqueous Media.非离子表面活性剂与水及各种同系酯的微乳液:制备、相变、物理性质测量以及从水介质中萃取三环类抗抑郁药物的应用
Nanomaterials (Basel). 2023 Aug 11;13(16):2311. doi: 10.3390/nano13162311.
2
A Lipid-Based In Situ-Forming Hexagonal Phase for Prolonged Retention and Drug Release in the Breast Tissue.一种用于延长在乳腺组织中保留时间和药物释放的基于脂质的原位形成六方相。
AAPS PharmSciTech. 2022 Sep 19;23(7):260. doi: 10.1208/s12249-022-02411-9.
3
Preparation and Characterisation of a Cyclodextrin-Complexed Mānuka Honey Microemulsion for Eyelid Application.
用于眼睑涂抹的环糊精复合麦卢卡蜂蜜微乳液的制备与表征
Pharmaceutics. 2022 Jul 19;14(7):1493. doi: 10.3390/pharmaceutics14071493.
4
Syngonanthus nitens Bong. (Rhul.)-Loaded Nanostructured System for Vulvovaginal Candidiasis Treatment.用于外阴阴道念珠菌病治疗的载有美丽水竹叶的纳米结构系统。
Int J Mol Sci. 2016 Aug 22;17(8):1368. doi: 10.3390/ijms17081368.
5
Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.用于治疗阿尔茨海默病的基于纳米技术的药物递送系统。
Int J Nanomedicine. 2015 Aug 4;10:4981-5003. doi: 10.2147/IJN.S87148. eCollection 2015.